Alpine Immune Sciences Inc (NASDAQ:ALPN) – Analysts at Oppenheimer increased their FY2019 EPS estimates for Alpine Immune Sciences in a note issued to investors on Wednesday, November 13th. Oppenheimer analyst M. Breidenbach now anticipates that the biotechnology company will post earnings per share of ($2.58) for the year, up from their prior estimate of ($2.65). Oppenheimer also issued estimates for Alpine Immune Sciences’ Q4 2019 earnings at ($0.63) EPS, FY2020 earnings at ($2.36) EPS, FY2021 earnings at ($2.35) EPS, FY2022 earnings at ($2.18) EPS and FY2023 earnings at ($1.71) EPS.
Other analysts also recently issued research reports about the stock. ValuEngine raised shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research raised shares of Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Monday. Finally, Piper Jaffray Companies lowered their price objective on shares of Alpine Immune Sciences to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $9.25.
Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings data on Wednesday, November 13th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.06. The firm had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.38 million.
A number of large investors have recently modified their holdings of ALPN. Vanguard Group Inc. grew its position in Alpine Immune Sciences by 67.7% in the second quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock valued at $853,000 after acquiring an additional 81,800 shares in the last quarter. Hikari Power Ltd grew its position in Alpine Immune Sciences by 52.9% in the third quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock valued at $735,000 after acquiring an additional 64,224 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Alpine Immune Sciences in the second quarter valued at approximately $90,000. Renaissance Technologies LLC grew its position in Alpine Immune Sciences by 10.8% in the second quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock valued at $447,000 after acquiring an additional 10,400 shares in the last quarter. Finally, Leonard Rickey Investment Advisors P.L.L.C. acquired a new stake in Alpine Immune Sciences in the second quarter valued at approximately $42,000. 47.16% of the stock is owned by institutional investors.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Featured Story: Gross Domestic Product (GDP)
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.